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Abstract 
In essence, pharmacogenetic research is aimed at discovering variants of importance to gene-
treatment interaction. However, epidemiological studies are rarely set up with this goal in mind. 
It is therefore of great importance that researchers clearly communicate which assumptions 
they have had to make, and which inherent limitations apply to the interpretation of their results. 
This review discusses considerations of, and the underlying assumptions for, utilizing different 
response phenotypes and study designs popular in pharmacogenetic research to infer gene-
treatment interaction effects, with a special focus on those dealing with of clinical effects of 
drug treatment.  
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Introduction 
Pharmacogenetics can be thought of as a classic example of gene-environment interaction. 
Namely, in the search for genetic variation which can explain inter-individual drug response 
variability, researchers typically aim to answer the question whether a treatment effect differs 
between subjects with different genotypes. In other words, whether an inherited genetic variant 
acts as an effect measure modifier for a certain (drug) treatment. 
Although the term pharmacogenetics was coined halfway through the 20th century by Fredrich 
Vogel (1), widespread interest into the field truly emerged with the completion of the Human 
Genome Project (2) (Figure 1). There now exist large publically available web resources and 
pharmacogenetic databases, made possible by methodological advances in sequencing 
technology and the emergence of genome-wide testing strategies (3, 4). Regrettably, 
contemporary pharmacogenetic research often depends on the type of study data readily 
available, as most epidemiological studies are not developed with pre-specified 
pharmacogenetic research questions in mind. Therefore, a heterogeneous body of literature 
exists. Collective interpretation can be difficult, as limitations and assumptions inherent to 
different epidemiological study designs must be recognised. Unfortunately, there also exist 
notable examples in the literature where authors overextend the scope and significance of their 
findings.  
Here, we discuss considerations relating to different response phenotypes and study designs 
typically found throughout the pharmacogenetic literature. Though many of the considerations 
and pitfalls described in this paper will also apply to other types of pharmacogenetic 
investigations (e.g. those focussing on ADME properties), we will especially focus on studies 
dealing with clinical effects of drug treatment, an area where we feel invalid inference is more 
prevalent or at least more visible. We will clarify which conclusions may be drawn and which 
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limitations naturally follow from which methodological approach. Where applicable we 
provide illustrative examples from the field of statin pharmacogenetics, in which a diverse 
range of phenotypes and study designs have been combined and investigated (5). Here, we will 
focus specifically on investigations into the intended effects of cholesterol reduction, on the 
prevention of vascular events, or on the unintended occurrence of myopathy-related complaints 
after starting statin therapy.  
 
Response phenotypes 
Except for sharply defined clinical outcomes such as mortality, effects of treatment can often 
be visualised as lying on a possible spectrum of outcomes. For example, the clinical spectrum 
of statin-induced myopathy ranges from commonly occurring myalgia to very rare incidents of 
life threatening rhabdomyolysis (6). The narrow approach of dichotomization will thus lead to 
a loss of information and possibly reduced statistical power (7). This may particularly be the 
case for drug efficacy or toxicity phenotypes related to drug dosage. Furthermore, 
dichotomizing outcomes may induce unnecessary phenotypic heterogeneity between studies 
(complicating systemic reviews and meta-analyses), and might conceal possible non-linearity 
in the associations under investigation. Therefore, continuously distributed outcome-traits are 
often preferable when available. However, these outcomes come with their own challenges (e.g. 
non-normal distributions), and may hinder translating the results to clinically meaningful 
findings. For example, prior knowledge of clear clinical bimodality (e.g. disease remission) 
may guide researchers in choosing a response phenotype which most closely aligns with the 
biology of interest. In addition, dichotomous outcomes more often allow for simple visual 
presentation of results and categorization may mitigate the effects of including significant 
outliers in your analysis. 
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Most pharmacogenetic investigations of interest are inherently longitudinal in nature, as one 
wishes to measure a phenotype just before and then after a drug treatment has started. This goal 
corresponds to a criterion essential to causal inference, namely temporality: that exposure 
preceded the outcome (i.e. onset of disease or change over time in a trait) (8). Even for binary 
outcomes (e.g. clinical or adverse events) it will be essential to compare incidence between 
drug exposure categories, including the absence of drug exposure. Whenever possible, 
incorporating both on- and off-treatment observations into the data analysis is therefore 
considered superior to solely basing conclusions on data from one or more observations made 
on-treatment. There exist additional reasons why utilizing repeated measurements is often 
preferable for quantitative traits. Firstly, a single measurement is merely a snapshot of the 
underlying response-curve, not representative of the true response characteristics over the 
whole treatment phase, which is likely to differ per individual (9). Secondly, methods that do 
involve baseline values can eliminate much of the between-subject variability from the 
treatment comparison, and are therefore typically more powerful. Thirdly, limiting the analysis 
to a single on-treatment value ignores possible baseline imbalances between the groups, which 
are likely to occur in non-randomised studies. Taking these into account may help to control 
for confounding by (contra)indication and in distinguishing genetic effects on the response 
phenotype from those on off-treatment levels. Finally, having both on- and off-treatment 
measurements allows for the calculation of change over time, which is easy to communicate to 
a broad non-statistical audience.  
A further consideration is the selection of a valid time interval to assess treatment response, 
which should be based on clinical experience. For example, a steady-state in low-density 
lipoprotein cholesterol (LDL-C) may be expected 4-6 weeks after start of statin treatment (10). 
However, when one is interested in onset of myopathy symptoms a longer period should be 
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considered, e.g. the mean duration of statin therapy before onset of symptoms was 6.3 months 
(range 0.25-48.0) in a retrospective study of 45 patients (11).  
For adverse drug reactions, response phenotypes suitable for pharmacogenetic research will 
generally be those which appear to be strongly tied to the drug exposure. This will often depend 
on baseline disease incidence, whether relative effect sizes observed in large-scale studies are 
of apparent clinical importance, but also whether sufficient evidence supports a causal link 
between the drug exposure and the adverse event. Additional practical considerations such as 
data availability may guide or limit researchers in their investigations. For example, while it 
has been reliably shown that new-onset diabetes mellitus may be caused by statin therapy (12), 
repeated glucose measurements have historically not been assessed within statin trials. This 
likely explains why statin-induced glucose changes have not been examined in the 
pharmacogenetic setting to date. 
 
Defining treatment effect 
The observed average treatment response in a study does not always reflect the benefit of the 
treatment per se, as the context wherein this observation is made is of great importance (Figure 
2). This is because an individuals’ treatment response, defined here as the clinical outcome 
after starting the treatment, is not just a combination of the drug effect (i.e. the underlying 
(un)measured physiochemical response) and the natural course of the disease, but may also 
reflect secondary effects of initiating drug treatment (13, 14). Examples include placebo effects, 
the possibility that the individual may have been motivated to concurrently alter lifestyle habits 
of prognostic significance to the outcome of interest, or that the researcher or study participant 
may (un)knowingly influence the measurement of the endpoint if he/she is aware of the purpose 
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of the study (i.e. observer bias) (14). The latter issue is more likely to occur with subjective 
outcomes, but may be avoided through blinding both researcher and study participants.  
A serious problem in non-randomized studies is the issue of confounding by (contra)indication. 
In routine healthcare the decision to initiate or refrain from drug treatment is based on the 
prognosis of the patient. Consequently, the prognoses of treated and untreated individuals in 
observational studies are typically not comparable. In other words, individuals with more 
indications for treatment are more likely to be treated, but also more likely to have a worse 
outcome. If this is not taken into account through study design or statistical adjustment, 
straightforward inference of treatment benefits may be invalid, as it could seem that treatment 
actually leads to worse outcomes (15). While no statistical adjustment method can fully resolve 
confounding by (contra)indication in observational studies if not all confounders are known, 
its effects should be minimized when possible. Given that genotype is set at conception and 
remains fixed throughout life, confounding by (contra)indication is unlikely to bias the effect 
estimate of a genetic variant on the outcome of interest. However, if confounding bias is present 
for the association between the drug exposure and the outcome of interest, this may in select 
cases carry over to the assessment of interaction between the genetic variant and this drug 
exposure (16). 
In the next sections we show that the degree to which different study designs are able to avoid 
or disentangle these considerations is paramount to the interpretation of results and conclusions 
that can be drawn, also in the field of pharmacogenetics.  
Study designs 
Various studies are available and appropriate to answer different types of pharmacogenetic 
research questions, depending on the stage of drug development. Here we focus on those 
suitable to evaluate the effect of genetic variation on treatment efficacy and adverse drug 
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reactions, questions which will typically be asked after a drug has already been approved for 
clinical use. In addition to post-hoc subgroup analyses within a randomised controlled trial 
(RCT), all traditional population-based epidemiological studies can be used in this phase.  
However, all study designs come with underlying assumptions and limitations, and may not be 
able to answer all relevant questions (Table 1).  
Our discussion here focuses mostly on sources of bias general to all epidemiology. However, 
a source of confounding specific to genetic epidemiology concerns population stratification 
(17). If there exist subgroups of individuals within the study population which differ in terms 
of genotype frequency and disease risk, spurious associations may arise if this is not taken into 
account. Typically, this can occur when individuals from different ethnic backgrounds with 
limited admixture are included in the same analysis (18). However, even apparently 
homogenous populations may contain genetically distinct subgroups (19). As larger samples 
will likely be more heterogeneous, population stratification will be a larger problem here  (17).  
This should be of particular concern to researchers involved in the field of drug-gene 
interaction, where large studies are typically necessary to find promising signals. 
 
Outcome-based designs 
The case-control design is perhaps the most common approach for pharmacogenetic 
investigations into clinical effects, often focussing on adverse drug reactions. Sampling is 
based on the outcome, with individuals who did (cases) develop the outcome of interest being 
compared to those who did not (controls), with regard to drug exposure prevalence and 
genotype frequencies. Case-control studies can be used to assess both main effects of the 
genetic variant and drug exposure on the outcome, but may also assess interaction on the 
additive and multiplicative scale (20) (Table 2).  
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There also exist case-control studies which solely include individuals with known drug 
exposure, in which the analysis is limited to comparing genotype frequency between cases and 
controls. For the purpose of simplicity we will assume throughout the manuscript and tables 
that a particular susceptibility genotype is classified as being either present or absent. If it can 
be assumed that genotype does not associate with the outcome of interest in the absence of drug 
exposure, potential differences in disease occurrence between genotype groups can be 
interpreted as gene-treatment interactions (21). Whether this assumption is valid is highly 
dependent on the outcome of interest and the observation window chosen to assess this 
outcome. For example, this assumption is likely to hold for LDL-C reduction after statin 
treatment, since genetic variants are unlikely to lead to such acute (i.e. within days/weeks) and 
significant LDL-C changes (~30%) in absence of the drug treatment. In contrast, a treated-only 
case-control study on the occurrence of coronary artery disease after statin use is likely to also 
turn up genetic variants affecting risk in absence of statin treatment, as the underlying 
atherosclerotic process has a much slower onset than statin-induced LDL-C reduction.   
Major benefits of the case-control design are its cost-effectiveness compared to large cohort 
studies, but more importantly that it is highly suited for rare (drug) outcomes. For severe 
adverse drug reactions, it may sometimes even form the only realistic approach to examine 
genetic contributions. When the outcome of interest has a continuous distribution, sampling 
individuals from the extremes of the outcome distribution (e.g. comparing high- with non-
responders in LDL-reduction after starting statin treatment) may greatly increase statistical 
power when faced with budgetary restrictions for genotyping (22). However, as shown for non-
responders to statin therapy in the PROspective Study of Pravastatin in the Elderly at Risk 
(PROSPER) trial, issues of treatment non-adherence are especially important to consider here 
(23). This strategy may also be promising when rare variants are investigated, as their 
prevalence may be greater on the extreme ends of the outcome spectrum (24). 
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There are some notable challenges in performing case-control studies, the first and foremost 
being the selection of an appropriate control group. The control group should be representative 
of the source population in terms of exposure distribution and genetic ancestry (e.g. European, 
Asian or African ancestry), and should ideally consist of individuals who would be classified 
as cases if they had developed the outcome of interest. In other words, controls should meet 
the eligibility requirements for cases except for their outcome status (20). Preferably, a 
geographically defined population should be the source of sampling, so the entire at-risk 
population can be enumerated. For hospital- or clinic-based case-control studies it may be 
difficult to identify this source population, as it does not correspond to a specific geographical 
area. For example, trauma victims referred to the hospital could live nearby or have been flown 
in by helicopter. In general, the catchment area for a hospital or clinic is likely to differ for 
different diseases, which will need to be considered when sampling controls. Similarly, as the 
cases of outcome-based studies on adverse drug reactions are often identified through databases 
it may be difficult to recruit an appropriate control group, especially since these events are 
often underreported (25, 26). Case-control studies nested within an existing cohort may fare 
better in this regard. A further risk is that cases with short survival times may be 
underrepresented if collection of (genetic) data occurs sometime after the event of interest.  
An alternative outcome-based design is the case-only study, wherein the analysis is restricted 
to cases (Table 1). This simple approach, which can evaluate gene-treatment interaction on the 
multiplicative scale, assumes that genotype and drug treatment are not correlated in the 
population that gave rise to the cases. Under this assumption this design increases power for 
the test of interaction, thereby lowering the number of cases needed to be genotyped (27). Not 
having or being able to find a suitable control group is another reason why this may be an 
attractive alternative to the conventional case-control study (28). If nested in a RCT the 
distributions of gene and treatment can be assumed to be independent by virtue of 
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randomisation, making the case-only odds ratio a valid measure of gene-treatment interaction 
(Table 2). The calculated odds ratio may however (slightly) differ between case-control and 
case-only studies, as case-control studies estimate different population parameters (odds-, rate-, 
or risk-ratio), depending on how the controls were sampled (29). An example of the case-only 
approach in the field of statin pharmacogenetics is that by Schiffman and colleagues, who 
performed a genome-wide association study on coronary heart disease risk reduction when 
being treated with pravastatin therapy (30). In the discovery phase they solely included 
coronary heart disease cases from the Cholesterol and Recurrent Events (CARE) trial and the 
West of Scotland Coronary Prevention Study (WOSCOPS) trial, finding that 79 common 
genetic variants were nominally (P<10-4) associated with differential event reduction by the 
therapy. To validate these results, these variants were then genotyped in an additional placebo-
controlled pravastatin trial, and in all remaining patients from CARE and WOSCOPS (with or 
without event) (30). This study thereby exemplified how the case-only approach could be 
utilized as a cost-saving measure, by first screening the genome for promising signals, before 
including controls. 
Nesting a case-only study within a cohort study can be problematic, as it is possible that genetic 
factors could influence the ability to tolerate therapy. Therefore, independence between 
genotype and treatment may not be a valid assumption. While this could also occur within an 
RCT, this experimental study design is more likely to have information on, and be able to 
include in the analysis, enrolled individuals who did not respond or had severe side effects. It 
has been argued that tests of gene-treatment association in controls may indicate whether 
genotype and treatment are truly independent in the source population, if the outcome is 
sufficiently rare (31). If however the assumption of gene-treatment independence is violated 
and ignored, the case-only approach will provide a biased interaction effect and lead to 
increased false-negative results (32). Another limitation of the case-only design is that main 
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effects of either genetic or drug treatment on the outcome cannot be estimated, and inference 
is limited to examining interaction on the multiplicative scale. More generally, all outcome-
based designs which cannot approximate risk ratios (rare disease assumption) or risk 
differences (due to knowing sampling fractions) are unable to examine interaction on the 
additive scale, which is often of greater public health relevance (33). Due to their observational 
nature, outcome-based studies are additionally highly prone to confounding, selection bias (i.e. 
that the association between (drug) exposure and disease differs for participants who were and  
were not included in the study) and information bias (i.e. systematic error in the approach 
adopted for measuring or collecing data from a study) (20). For the last category, especially 
recall bias can pose an issue, which will not apply to genotype but might to drug history. 
 
Cohort-based designs 
Cohort-based designs include the cohort and treated-only designs (Table 1). Typically, the rate 
of occurrence (or recurrence) is compared between individuals with different drug exposures 
levels. Increasingly, population-based cohort studies are undertaken, in which an ideally 
random sample or even the entirety of a defined population is included in which multiple 
hypotheses can be evaluated. Though these relatively expensive and time-consuming studies 
aim to answer the same questions of causality that outcome-based designs do, the extensive 
and repeated phenotyping and follow-up allows for more flexibility in investigating multiple 
outcomes and recent, prior and repeated drug exposure (21). In addition, studying a cohort 
representative of a defined population allows for the calculation of population attributable risks. 
While this type of study typically includes more participants than outcome-based studies, it is 
unlikely that a single study would be able to overcome the power and sample size issues 
associated with genome-wide testing. Considerations of sample size are discussed in detail in 
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a separate section below. As cohort-based designs do not typically allow for blinding of 
researchers and participants, it is very likely that observer effects will not be equal between the 
treatment groups. In addition, if genetic testing was not undertaken close to commencement of 
treatment, selection bias may occur when non-responders or those with severe side effects are 
absent from the population.  
Of greater issue is that the assignment of drug therapy is likely to have been subject driven. 
This means that the prognoses of the treated and untreated subjects will generally not be alike. 
In addition to this previously discussed confounding by (contra)indication, the issue of 
regression-to-the-mean may be problematic here. This occurs because the group of subjects at 
the extremes of the response distribution at baseline not just consists of those who consistently 
have more extreme values compared to the population average, but also those who simply by 
chance had an extreme value at baseline. Subsequent measurements of those who fall in the 
second category will therefore tend to be closer to the population mean thereof. Observed 
phenotypic changes over time may thus (partially) represent this regression-to-the-mean, which 
can occur when participants and/or treatment are selected on phenotypic cut-offs at baseline. 
This statistical phenomenon has been demonstrated for a wide range of biological measures, 
including lipid levels (34). Therefore, in non-randomised studies, it should be considered to 
combine multiple baseline measurements to reduce measurement error when selecting subjects, 
or to use suitable statistical methods (35, 36).  
The treated-only design essentially tries to limit the issue of confounding by contraindication 
whilst improving statistical efficiency (37). As the name suggests, this design limits the 
analysis to those exposed to the drug, thereby leaving out the subjects who might have had a 
pertinent contraindication to treatment. This contrasts with cohorts which do include an 
untreated control group, in which confounding by (contra)indication is more commonly 
addressed through statistical adjustment, although applying stricter inclusion criteria at 
14 
 
enrolment may also limit this issue (14). A clear benefit of the treated-only approach is that 
less individuals are required for the analysis, which can be highly advantageous when 
genotyping study participants. As noted for the treated-only outcome-based design, the central 
assumption for inferring gene-treatment interaction effects here is that the genetic variant is 
unlikely to explain change in outcome in absence of the drug exposure (21). A clear drawback 
are that the main effects of genetic variants on the outcome are inseparable from drug-treatment 
interaction effects. Observed loci may thus be associated with the natural course of the disease 
(37). In these cases, leveraging publically available data from genome-wide association studies 
(GWAS) may help to substantiate the claim of absence of a main effect of a genetic variant on 
the outcome of interest. This approach will however require these GWAS to have taken into 
account possible effects of drug treatment and to have a similar outcome definition. 
Of special note, an increasing number of researchers are utilizing (singular or repeated) cross-
sectional data from cohort studies to perform genome-wide gene-treatment interaction analyses 
for quantitative traits (38). These efforts have largely been motivated by the issue that the 
design of many cohorts is not ideal for measuring longitudinal drug-induced changes. 
Specifically, assessment may be problematic when drug exposures are rare, when large 
intervals of time separate repeat drug exposure assessment, and when outcome phenotypes are 
not collected at each study visit. Therefore, the use of repeated exposure cross-sections allows 
for more cohorts to contribute, noting that increases in power from including more participants 
has been shown to be larger than the modest increase in power from making use of repeat cross-
sectional measures in the same participants (39).  To date, this approach has particularly been 
applied to questions of gene-treatment interaction for different drug classes on 
electrocardiography-markers (39, 40). Similar research efforts are currently underway for the 
field of statin pharmacogenetics.  
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As study information on exposure and outcome is typically determined at the same time, or at 
least analysed without regard for differences in time, the temporal relationship between 
exposure and outcome remains unclear in these cross-sectional analyses. In fact, making a 
distinction between exposure and outcome will generally not be possible, unless a well-
established drug response phenotype is available (20). Furthermore, aside from the issues 
discussed previously concerning the use of a single on-treatment measurement, care must be 
taken to differentiate effects from those on off-treatment values. Therefore, formal comparison 
with an untreated group is to be advised. Alternative explanations for detected associations 
between genotype and outcome may be differences in number and duration of previous 
treatment(s) and differences in severity of disease. Using data from established cohorts may 
greatly facilitate the execution of these investigations. Nonetheless, due to their inherent 
limitations, cross-sectional studies are most suitable as hypothesis-generating tools for slowly 
developing diseases without sharp onset times, rather than for making solid pharmacogenetic 
inferences of gene-treatment interaction. 
 
Randomized Controlled Trial  
While similar in design to a cohort with a control group, the key difference for the RCT is that 
drug treatment is randomly allocated. As this ensures that the predictors of the outcome are 
equally distributed between the treated and untreated group, we can assume that: “the treated, 
had they remained untreated, would have experienced the same average outcome as the 
untreated did, and vice versa” (41). In addition, this strategy enables blinding of researcher and 
participant, which aims to prevent subsequent differential co-interventions or biased 
assessment of outcomes (42). As previously noted, if the trial is of adequate size the 
distributions of genotype and exposure will be independent. Due to these study characteristics, 
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it is possible to either avoid or account for regression-to-the-mean, confounding by 
(contra)indication, and selection bias. Consequently, it is possible to make more firm 
conclusions regarding the underlying treatment effects than is possible in non-randomised 
studies (Figure 2). While reducing the likelihood of selection bias is a major appeal of RCTs, 
it should be noted that genotyping in blood samples taken after study completion may still 
introduce this problem. 
Subgroup analyses in trials have also been criticized (43), but “breaking” the randomisation 
will typically only occur if researchers condition on a variable that occurs after treatment, 
which will not apply to genotype. Though RCTs are considered the gold standard to estimate 
unbiased drug-SNP interaction effects, a variety of reasons exist which explain why researchers 
may prefer observational study settings instead. Trials will typically have included a select 
number of participants, thus leading to reduced statistical power compared to large 
observational cohorts. In addition, the relative limited number and narrow definition of 
exposures and outcomes under investigation may allow for less flexibility for pharmacogenetic 
enquiries. For example, both drug exposures and outcomes may be more clinically meaningful 
when examined as classes not envisioned when designing the trial. Other considerations 
include concerns of generalizability due to RCTs often having strict exclusion criteria, and that 
the RCT approach is even less suited than the cohort-based designs to investigate rare adverse 
outcomes. This results from individuals with relevant co-morbid conditions or with severe side 
effects typically being excluded before randomisation (e.g. during a run-in phase), in addition 
to trials often not having adequate follow-up to investigate outcomes which can occur long 
after the invention (44).  
An approach analogous to that of the RCT, known as Mendelian randomisation, is increasingly 
being used in the context of pharmacogenetics and pharmacovigilance. These investigations, 
in which the causal effect of an exposure on an outcome is assessed by using a genetic proxy 
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(e.g. one or multiple genetic variants) instead of the exposure (45), have been applied to a range 
of different types of questions. For example, summary level statistics from a large-scale 
pharmacogenetic meta-analysis of GWAS of statin-induced lipid response were recently used 
to demonstrate that genetic predisposition for increased LDL-C levels may decrease efficacy 
of statin therapy if effects on off-treatment lipid levels are taken into account (46). Mendelian 
randomisation might alternatively be used to predict unintended drug effects. For example, 
Swerdlow and colleagues used SNPs in the HMGCR (i.e. the enzyme targeted by statins) gene 
to demonstrate that the increase in new-onset type 2 diabetes risk is “at least partially” 
explained by HMGCR inhibition (47). In theory, Mendelian randomisation investigations 
could reveal these effects prior to drugs licensing, potentially preventing exposure of large 
groups of patients to unnecessary risks (48). Lastly, stratifying Mendelian randomisation 
analyses could provide evidence which subpopulations are likely to derive greater benefit from 
a drug, which could guide future RCTs (49). 
 
Considerations of sample size 
A major issue in pharmacogenetic research has been the poor reproducibility of promising 
signals, likely in part due to underestimation of the sample sizes necessary to examine gene-
treatment interaction. It has previously been demonstrated that study sizes for investigations 
into interaction on the multiplicative scale should be over four times as large as those necessary 
to detect main effects of the same magnitude (50). Given the relatively small effect sizes 
involved, it should therefore not come as a surprise that necessary sample sizes can run into 
the tens of thousands when genome-wide strategies are considered, where one must not just 
account for multiple testing but also consider the necessity of replicating ones results (51). 
Programs for sample size and power calculations for gene-treatment interaction have also been 
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used to estimate sample size requirements for investigations into clinical effects of statin 
therapy (5). In addition to study design, researchers must consider the expected sizes of both 
the genetic effect and the drug response, the size of their interaction effects, allele frequencies, 
mode of inheritance, and the prevalence of the drug treatment and outcome. Moreover, studies 
are likely to genotype variants in linkage disequilibrium with the true causal variant, which will 
also influence sample size requirements (52). 
In recent years, data from mega-biobanks have been become increasingly available, which will 
provide unprecedented possibilities for pharmacogenetic enquiries. It should however be noted 
that participation rates have been relatively low, which will pose unique challenges when 
interpreting results. For example, only 5.2% of the 9.2 million individuals invited to enter the 
population-based UK Biobank actually participated in the baseline assessment (53). Similarly, 
in mid-2015 the Million Veterans Program estimated their response rate at 13.2% of the first 3 
million invited individuals (54). In addition, it is highly questionable whether signals which 
can only be detected under these increased sample sizes will actually translate into clinically 
meaningful results. 
Further considerations must be made when multiple study designs are incorporated in the same 
analysis via a meta-analytic approach. In the next section we will examine some of these 
considerations, taking the largest pharmacogenetic meta-analysis of genome-wide association 
studies of statin-induced LDL-C changes as an example (55). 
 
Genomic Investigation of Statin Therapy (GIST) consortium 
A major limitation of previously performed individual pharmacogenetic studies of statins was 
the lack of statistical power to detect small pharmacogenetics effects. To overcome this 
problem, a large meta-analysis of all available data on statin response was initiated, in which 
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the investigators aimed to combine results from statin trials and large-scale cohorts. For their 
meta-analysis on differential response in LDL-C to statin therapy, the GIST consortium 
included 6 statin-trials (n=8,421) and 10 observational studies (n=10,175) for the discovery 
stage. Thereafter, the most promising signals were validated in a further 22,318 subjects. 
Within this large GWAS effort, four loci were found to be associated with LDL-C lowering 
response to statin therapy. The most significant association was for a SNP on chromosome 6, 
at LPA (rs10455872, minor allele frequency (MAF)=0.08, beta=0.052, standard error 
(s.e.)=0.004, P=7.41x10-44), indicating that carriers of the rs10455872 SNP respond to statins 
with a 5.2% smaller LDL-C lowering effect per minor allele compared with non-carriers. The 
second strongest was a SNP at APOE on chromosome 19 (rs445925, MAF=0.11, beta=-0.051, 
s.e.=0.005, P=8.52x10-29), indicating an additional 5.1% increase per allele in LDL-C lowering 
effect compared to non-carriers. In addition, SNPs at two novel GWAS loci were shown to be 
significantly associated with statin response: SORT1/CELSR2/PSRC1 at chromosome 1 
(rs646776, MAF=0.22, beta=-0.013, s.e.=0.002, P=1.05x10-9) and SLCO1B1 at chromosome 
12 (rs2900478, MAF=0.16, beta=0.016, s.e.=0.003, P=1.22x10-9). 
Notably, the consortium solely included statin-users, which made it possible to compare 
associations found in trials with those of observational studies. In addition, this approach made 
it possible to gather large enough numbers, given the necessity to account for multiple testing. 
To mimic the trial setting as close as possible, only incident statin users with a pre- and post-
measurement were included from observational studies.  
As discussed previously, the central assumption for inferring gene-treatment interaction effects 
via this treated-only approach is that genotype should be unlikely to significantly correlate with 
the response in absence of drug exposure. Given that the underlying disease course (i.e. LDL-
C levels) can be assumed to be quite stable in absence of lipid-lowering treatment, this 
assumption may very well be valid. In addition, placebo- and observer-effects will likely be 
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near absent for statin-induced LDL-reduction, which will exist for more subjective complaints 
such as those seen within the field of psychiatric pharmacogenetics (56). The suitability of this 
approach was reinforced by the large homogeneity of estimates when RCTs and observational 
studies were separately considered.  
A major point of discussion however surrounded the question how to account for the possible 
effect of genetic variants on off-treatment values, which cannot simply be accounted for by 
taking the (fractional) difference between on- and off-treatment levels as the outcome. In the 
end, the researchers solely included participants with on- and off-treatment LDL-C levels. Each 
study independently performed a GWAS on the difference between the natural log-transformed 
LDL-C levels on- and off-treatment which can be interpreted as the fraction of differential 
LDL-C lowering in carriers versus non-carriers of a genetic variant. These analyses were then 
adjusted for natural log-transformed off-treatment values to try to distinguish drug-treatment 
interaction effects from genetic effects on off-treatment LDL-C levels, a strategy for which 
there exists extensive debate, particularly for non-randomised studies (57, 58) By performing 
additional analyses, the researchers were however able to validate this approach. These 
included calculating formal gene-treatment interaction terms within a trial not involved in the 
first-stage meta-analysis for the genetic variants found to be genome-wide significant, but also 
by adjusting for the measurement error and intra-individual variation in off-treatment values in 
the only study which had multiple baseline measurements available (59).  
The main limitation of the analysis is the large degree of clinical heterogeneity. This is 
evidenced not only by differences in eligibility criteria of the original studies, leading to the 
inclusion of different patient groups, but also by differences in statin types (n=8) and dosages. 
While adjustment for statin dose was achieved by dividing the dose by the statin-specific dose 
equivalent based on daily dosages required to achieve mean 30% LDL-C reduction, changes 
in dose during follow-up could not be taken into account.  Nonetheless, the project remains a 
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clear example that if certain assumptions can be realistically met, inherent limitations to 
pharmacogenetic inference may be overcome.  
 
Conclusion 
Pharmacogenetic research is an expanding field, whose relevance is slowly becoming visible. 
While post-hoc subgroup comparisons in RCTs are still considered the gold standard in 
pharmacogenetic research of treatment efficacy, there exist many research questions for which 
RCTs cannot provide the solution. As all study designs and response phenotypes have their 
merits and problems, authors should be vigilant to avoid making conclusions which their 
methodology cannot back up. In particular, the assumptions needed to make inferences on 
gene-treatment interaction must be carefully considered, especially when case-only or treated-
only strategies are employed. These challenges to inference remain ever relevant as new 
avenues of pharmacogenetic investigations emerge, including those using epigenetics or 
mRNA, as these studies will typically be performed in similar research settings.  
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Figure legends 
Figure  1. Appearance of the terms pharmacogenetic(s) or pharmacogenomic(s) in PubMed-
indexed publications across the past 25 years. The Human Genome Project was completed in 
2003. 
 
Figure 2. Non-randomized study on treatment response. The observed treatment response to 
drug X depends not just on the underlying physiochemical response and natural course of the 
disease process, but also on secondary effects of being allocated drug X. Moreover, 
confounding by (contra)indication may occur if reasons to initiate or refrain from drug 
treatment also associate with the outcome of interest. Pharmacogenetic research aims to answer 
which, if any, inherited genetic factors explain variation in the outcome of interest in the 
presence of a certain (drug) treatment (i.e. drug-gene interaction effects), distinguishing these 
effects from direct (i.e. main genetic effects) on the outcome.  
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Table 1. Popular epidemiological study designs suitable for pharmacogenetic research questions on clinical effects of drug therapy 
Design Graphical representation Key assumptions for gene-treatment interaction Advantages Limitations 
Outcome-based designs 
Case-control 
 
Valid control selection 
Cost-effective; can evaluate rare 
events caused by rare variants; can 
assess both main and interaction 
effects 
Prone to selection/information bias and 
confounding due to observational design 
Treated-only 
case-control 
 
As case-control; no association between 
genotype and outcome in untreated group 
Genotyping untreated individuals not 
needed 
See case-control; can only assess 
interaction on multiplicative scale  
Case-only, 
nested within 
RCT 
 
No association between genotype and 
drug exposure in source population 
More efficient than case-control in 
evaluating interaction effects; 
genotyping controls not needed 
See case-control; can only assess 
interaction on multiplicative scale; gene-
treatment independence assumption 
unlikely to hold in non-randomised 
cohort 
Cohort-based designs 
Cohort  
 
- 
Repeated measures; can study 
multiple outcomes and rare exposures; 
can evaluate both main and interaction 
effects, can assess population-
attributable risk 
Subject-driven assignment of treatment; 
resource-intensive; prone to differential 
loss-to-follow up (selection bias); prone 
to information bias and confounding; 
inefficient for rare outcomes 
Treated-only 
cohort 
 
No association between genotype and 
outcome in untreated group 
Avoids issue of confounding by 
contraindication; more efficient than 
cohort study in evaluating interaction 
effects 
See cohort; can only assess interaction 
effects; prior knowledge necessary to 
make key assumption for gene-treatment 
interaction 
Trial-based design 
Subgroup 
analyses 
within RCT 
 
Valid randomisation procedure 
Random allocation of treatment 
assures comparability at baseline; 
regression-to-the-mean can be taken 
into account; allows for blinding 
Resource-intensive; limited 
generalizability; inefficient for rare 
outcomes 
RCT denotes randomised controlled trial 
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Table 2. Comparison of effect estimators from outcome-based study designs 
Case-control setting (frequency data complete) 
Drug (E) Genotype (G) Cases Controls Effect estimator 
- - a b  
- + c d ORG = b*c / a*d 
+ - e f ORE = b*e / a*f 
+ + g h ORGE = b*g / a*h 
To assess for interaction on the multiplicative scale: ORGE / (ORG * ORE) 
Treated-only case-control setting (subset of frequency data) 
Drug (E) Genotype (G) Cases Controls Treated-only case-control OR = f*g / e*h 
- - n/a n/a If the genetic variant G is not associated with the 
outcome among untreated individuals (ORG=1), the 
treatment-only case-control OR will estimate the 
assessment of interaction on the multiplicative scale 
from the case-control setting. 
- + n/a n/a 
+ - e f 
+ + g h 
Case-only setting (subset of frequency data) 
Drug (E) Genotype (G) Cases Controls Case-only OR = a*g / c*e 
- - a n/a If the drug treatment E and genetic variant G are not 
associated among controls (i.e. source population), 
the case-only OR will estimate the assessment of 
interaction on the multiplicative scale from the case-
control setting. 
- + c n/a 
+ - e n/a 
+ + g n/a 
OR denotes odds ratio. While the above table denotes genotype as the presence of absence of a certain susceptibility 
genotype, it will equally hold for more complex situations, including combinations of alleles at multiple loci. 
 
 
 
